Pleural Effusion Treatment Market Size, Share and Global Trend By Type (Transudate Effusion, Exudate Effusion), By Treatment (Quantitative Test Chest Draining, Pleurodesis, Thoracentesis, Pleuroperitoneal shunt, Catheter), By End User(Hospitals, Clinics, Ambulatory Surgery Centers) and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Pleural effusion is an abnormal condition in which excess fluid is present in the layers of pleura outside the lungs. In a normal condition, a small amount of fluid is already present in pleura in order to smoothen the breathing process. The treatment of pleural effusion includes removal of excess water from the lungs and diagnosing the cause of accumulating excess water in the lung and treating it. Certain causes such as heart failure, lung cancer, breast cancer, cirrhosis, leukemia, pulmonary embolism, kidney disease, lung infections, and ruptured esophagus are responsible for pleural effusion. According to the Labor Force Survey, 18,000 new cases in the U.K. are diagnosed with lung or breathing problem every year.
Rising prevalence of pleural effusion is a significant factor propelling the growth of the global pleural effusion treatment market. Also, the rising prevalence of lung injuries, lung tumors, congestive heart failure, and lymph or blood vessels blockages are further expected to expand the prevalence of pleural effusion. According to the European Society of Cardiology in 2014, an estimated 26 million people are suffering from heart failure worldwide.
To gain extensive insights into the market, Request for Customization
However, increased risk of infection, bleeding and collapsed lung are restraining factors for the global pleural effusion treatment market.
Key Players Covered
Some of the major companies that are present in the global pleural effusion treatment market Pixelenergy, HEYER Medical AG, Biometrix, Redax, B. Braun Melsungen AG, OAKWORKS® Medical, Bıçakcılar Medical Equipment AS, Smiths Medical and others. and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Type | · Transudate Effusion · Exudate Effusion |
By Treatment | · Quantitative Test Chest Draining · Pleurodesis · Thoracentesis · Pleuroperitoneal shunt · Catheter · Others |
By End User | · Hospitals · Clinics · Ambulatory Surgery Centers · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
In 2018, exculpate effusion accounted for the highest share in the type segment in the global pleural effusion treatment market due to an increased number of hepatitis and other viral borne diseases. The segment is projected to continue its dominance in the market share during the forecast period.
Key Insights
- Pricing Analysis by Key Regions
- Reimbursement Scenario for key countries
- Recent industry developments such as partnerships, mergers, and acquisitions
Regional Analysis
North America dominated the global pleural effusion treatment market in 2018, owing to rising prevalence of pleural effusion as well as heart-related diseases. According to the National Cancer Institute, an estimated 100,000 new cases are diagnosed with pleural effusion in the U.S. each year. According to Centers for Disease Control and Prevention, in 2016, 4.9 million people were suffering from chronic liver disease and cirrhosis in the U.S. Asia Pacific is anticipated to grow at a significant CAGR during the forecast period of 2019-2026, owing to rising prevalence of pleural effusion.
Key Industry Developments
- In April 2019, University of California, Los Angeles updated the progress and positive results of the studies of the tunneled pleural catheters for refractory effusions attributed to congestive heart failure (TREAT-CHF) TRIAL (TREAT-CHF).
- In January 2017, BD received U.S. Food and Drug Administration for the PleurX catheter system received for the use in specific non-malignant recurrent pleural effusions etiologies, including congestive heart failure.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
